Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
3 Inject this air into the bacteriostatic water vial, then draw out the water
Check out if youre eligible for the trial here, and check out a webinar on the study
Humans naturally make lactase in the brush border of the small intestine, but production often drops after childhood, which is why lactose intolerance is so common in adults.22 Among all digestive enzymes, lactase has some of the strongest evidence as a supplemental ingredient
The price-competition era is formally open
Bitter melon assisting in glucose regulation by promoting GLP-1 release